BetaGlue Technologies is a highly innovative company working in the Life Sciences sector. The Company has developed BAT-90, an advanced radiotherapy platform targeting inoperable solid tumors and/or surgical resection margins. BetaGlue is also patenting a medical device that enables safe biopsies in oncology, preventing even severe complications after lung or liver procedures. BetaGlue enjoys the support of a highly qualified Scientific Advisory Board, as well as of leading national and international advisers, in the development of its solutions.